Learning How GLP-1 Medicines Affect Liver Health in People with Type 1 Diabetes
This study looks at how GLP-1 RA medicines like Ozempic and Mounjaro affect the liver in people with type 1 diabetes (T1D) compared to people without T1D. We are focusing on a liver condition called metabolic dysfunction-associated steatotic liver disease (MASLD), which happens when too much fat builds up in the liver and can lead to other health problems. The goal is to find out if these drugs can treat MASLD in people with T1D.
Why this Research Matters
There is not much research on how common MASLD is in people with T1D, compared to what we know about people with type 2 diabetes (T2D). It is believed that people with T1D are more likely to get MASLD if they have high blood pressure, are older, have a higher body weight, or have had T1D longer. Medicines like Ozempic and Mounjaro help people with T2D, but we do not yet know how well they work for people with T1D.
What to Expect
If you choose to join this study, you will first fill out a short questionnaire to see if you qualify. If you qualify, you will be placed into one of five groups based on your medical history and the medicines you take. After that, you will fill out questionnaires about your health and daily habits, have a blood test, and get a liver ultrasound. If you do not have T1D, you will only have 1 study visit. If you have T1D and are not taking Ozempic or Mounjaro, or have taken them for more than one year, you will only have 1 study visit. If you have T1D and are not taking Ozempic or Mounjaro, you can be followed for up to one year if you start one of these medicines, with study visits every three months. The study will not provide these medicines to anyone, so you must be prescribed one of these medicines by a healthcare provider.
Study Duration
You may take part in the study for less than a day or up to one year, depending on your group. If you are followed for one year, you will have visits every three months.
Who can Participate
You may be able to join the study if you are between 18 and 80 years old. You must either not have diabetes or have had T1D for at least 15 years. If you do not have T1D, you must have overweight/obesity (your BMI must be over 25). If you have T1D, you must have never taken a GLP-1 RA medication like Ozempic or Mounjaro, or have been taking one for at least 1 year. You cannot join the study if you have had weight-loss surgery or if you are pregnant.
Study ID
Protocol Number: 25-2469
Compensation Information
Meet the Team
Scott Maclean
Principal Investigator